Next Article in Journal
DDX50 Is a Viral Restriction Factor That Enhances IRF3 Activation
Next Article in Special Issue
Characterization of Influenza D Virus in Danish Calves
Previous Article in Journal
Academ Virus, a Novel Hantavirus in the Siberian Mole (Talpa altaica) from Russia
Previous Article in Special Issue
Time-Dependent Proinflammatory Responses Shape Virus Interference during Coinfections of Influenza A Virus and Influenza D Virus
 
 
Article

Human SUMOylation Pathway Is Critical for Influenza B Virus

1
Department of Bioengineering, Institute for Integrative Genome Biology, School of Medicine, College of Engineering, Biomedical Science, University of California at Riverside, 900 University Avenue, Riverside, CA 92521, USA
2
Department of Microbiology, Global Health and Emerging Pathogens Institute, 1468 Madison Avenue, New York, NY 10029, USA
3
Department of Medicine, Division of Infectious Diseases, 1468 Madison Avenue, New York, NY 10029, USA
4
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Feng Li
Viruses 2022, 14(2), 314; https://doi.org/10.3390/v14020314
Received: 31 December 2021 / Revised: 24 January 2022 / Accepted: 26 January 2022 / Published: 3 February 2022
(This article belongs to the Special Issue Non-A Influenza 2.0)
The identification and elucidation of host pathways for viral infection are critical for understanding the viral infection processes and novel therapeutics development. Here, for the first time, we discover that the human SUMOylation pathway is essential for the IBV viral life cycle. First, IBV viruses were completely inhibited by a novel SUMOylation specific inhibitor, STE025, discovered from our FRET-based high-throughput screening, and the inhibition was very potent, with IC50~ 0.1 µM in an IBV-induced cell death rescue assay; Second, we determined that the IBV M1 protein was SUMOylated, which was mediated by the SUMOylation E2 conjugation enzyme and the E3 ligase enzyme at very high affinities, of 0.20 µM and 0.22 µM, respectively; Third, the mutation of the IBV M1 SUMOylation site, K21R, completely abolished the viral particle generation, strongly suggesting the requirement of SUMOylation for the IBV life cycle. These results suggest that the blockage of the host human SUMOylation pathway is very effective for IBV inhibition. We therefore propose that the host SUMOylation pathway is a critical host factor for the IBV virus life cycle. The identification and inhibition of critical host factor(s) provide a novel strategy for future anti-viral therapeutics development, such as IBV and other viruses. View Full-Text
Keywords: influenza B virus or IBV; critical host factor; SUMOylation; therapeutics influenza B virus or IBV; critical host factor; SUMOylation; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Dang, R.; Rodgers, V.G.J.; García-Sastre, A.; Liao, J. Human SUMOylation Pathway Is Critical for Influenza B Virus. Viruses 2022, 14, 314. https://doi.org/10.3390/v14020314

AMA Style

Dang R, Rodgers VGJ, García-Sastre A, Liao J. Human SUMOylation Pathway Is Critical for Influenza B Virus. Viruses. 2022; 14(2):314. https://doi.org/10.3390/v14020314

Chicago/Turabian Style

Dang, Runrui, Victor G. J. Rodgers, Adolfo García-Sastre, and Jiayu Liao. 2022. "Human SUMOylation Pathway Is Critical for Influenza B Virus" Viruses 14, no. 2: 314. https://doi.org/10.3390/v14020314

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop